ThinkingNode Life Science, Inc.

12:30 PM - 12:45 PM (PDT), Thursday, June 16, 2022
A paradigm-shift from pathway-centric to whole-cell-centric for drug R&D: TNL unique Whole-cell-centric Drug R&D Platform can generate on demand Patient Whole-cell Avatars. It is based on next-gen Unified Reasoning AI that combines both omics data and deep domain knowledge to provide a mechanistic multi-cellular profile of diseases across cell types/states.

Based on cause-n-effect whole-cell mechanisms, our Patient Whole-cell Avatars can be used to discover novel targets, disease pathways, and biomarkers, to test drugs in silico before lengthy and costly in vivo experiments, and to better design and optimize clinical trials. It has been successfully used for IBD and we extend our work on other autoimmune disorders, cancer, and central nervous system diseases.

The technology is mature. Its first generation has been successfully used in Dr. Pham first AI company (exit $637M). Combined, our multidisciplinary exec team (AI, Biology, Pharma, Medicine) has been involved in $12.5B exit.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Next-gen Whole-cell-centric Drug R&D Platform
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided